Abstract:Abstract Background Osteosarcoma (OS) is a genetically unstable malignancy that most frequently occurs in children and young adults. It has high incidence of metastasis and recurrence after treatment. The lack of progress in clinical management of this devastating disease prompts us to take a systems approach to profile key genetic alterations at the level of gene copy number aberration on a genome-wide scale and to interrogate the pathways that are critical for the hallmarks of OS. Our goal is to gain insight into potentially novel targets for therapeutics. Methods We conducted a high-density genome-wide array comparative genomic hybridization (aCGH) profiling with genomic DNA isolated from 10 fresh osteosarcoma tissues obtained from the Tumor Tissue Bank of the Tianjin Medical University Cancer Institute and Hospital (GSE19180). In addition, we downloaded aCGH data of an independent investigation from the GEO database (GSE9654). The patterns of the two independent aCGH data showed marked similarities. The pooled aCGH data were subjected to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis to identify altered pathways. Protein expression of specific genes was examined by immunohistochemistry (IHC) on 58 archival formalin fixed, paraffin embedded (FFPE) tissues and correlated with clinical follow-up information. Results Genome-wide aCGH analysis revealed that 1p35-1p35, 1q23.1-1q21.1, 6p22.1-6p21.31, and 19p13.11-p13.2 were significantly amplified, whereas 5q12.3-5q13.2, 5q14.3-5q22.2, and 13q13.2-13p14.3 were significantly deleted. These regions included 1,162 genes with amplifications and 146 genes with deletions. Pathway analysis showed that a number of cancer related pathways were significantly altered. These pathways included VEGF, cell adhesion, adherins junction, non-homologous end-joining, hedgehog signaling, and Wnt signaling pathways. Among the VEGF pathway genes, 13 genes including VEGFA itself were amplified. Detailed analysis showed that VEGFA protein expression (74.1%) was associated with microvascular density (MVD) (20.81±2.04 per mm2) and was an independent predictor for metastasis and/or recurrence (p=0.01). The aCGH analysis also led to the discovery that the tumor suppressor gene WWOX was deleted in 30% of OS. IHC analysis showed that loss of WWOX protein expression was even more frequent (61.8%), suggesting deletion of WWOX gene and ablated expression might be an important early event in OS pathogenesis. In addition, we found that the APEX1 gene was amplified in 60% in OS and the abundant expression of APEX1 protein (64.9%) was an independent predictor for the local recurrence and/or metastasis (p=0.04). Conclusions The systematic analysis of the genetic alterations has revealed involvement of multiple pathways in the pathogenesis and progression of OS suggesting that multi-pronged combinational therapy is needed for effective therapeutics. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2150.

Study of Osteosarcoma Related Genes and Individualized Treatment Based on High Throughput Genotyping

Individualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcoma

Identification of a Programmed Cell Death-related Signature for Prediction of Osteosarcoma

A clinical study of individual chemotherapy for osteosarcoma and chemosensitivity-related gene

Identification of Tumorigenicity-Associated Genes in Osteosarcoma Cell Lines Based on Bioinformatic Analysis and Experimental Validation.

Gene related chemotherapy resistance of osteosarcoma

Advances in targeted therapy for osteosarcoma based on molecular classification

Genomic Analysis Revealed Mutational Traits Associated with Clinical Outcomes in Osteosarcoma.

Potential Application of Genomic Profiling for the Diagnosis and Treatment of Patients with Sarcoma.

Pharmacogenetics of the Primary and Metastatic Osteosarcoma: Gene Expression Profile Associated with Outcome

Genetic Aberrations of Key Signaling Pathways in Human Osteosarcoma

Age-dependent molecular variations in osteosarcoma: implications for precision oncology across pediatric, adolescent, and adult patients

Identification of Key Genes and Pathways in Osteosarcoma by Bioinformatics Analysis

A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment

Mutational Landscape of Chinese Osteosarcoma Patients.

Genomic and transcriptomic characterization of pre-operative chemotherapy response in patients with osteosarcoma

Integrated Multiomic Analysis and High-Throughput Screening Reveal Potential Gene Targets and Synergetic Drug Combinations for Osteosarcoma Therapy

Abstract 2150: Genetic Alterations in the Major Pathways in Human Osteosarcoma and Their Clinical Significance

Genome sequencing analysis of blood cells identifies germline haplotypes strongly associated with drug resistance in osteosarcoma patients

Whole-exome sequencing in osteosarcoma with distinct prognosis reveals disparate genetic heterogeneity

Cmar_a_317809 5101..5111